Chingyuan (Rebecca) Li
About Chingyuan (Rebecca) Li
Chingyuan (Rebecca) Li is the Executive Director of Pharmaceutical Development at Erasca, Inc., where she has worked since 2019. She has extensive experience in pharmaceutical development, having held positions at several companies including Arena Pharmaceuticals, Medicis Pharmaceutical Corporation, Celera Genomics, and SUGEN.
Current Role at Erasca
Chingyuan (Rebecca) Li serves as the Executive Director of Pharmaceutical Development at Erasca, Inc. since 2019. In this role, she oversees the development of pharmaceutical products, focusing on advancing innovative therapies. Her leadership contributes to the strategic direction and execution of projects aimed at improving patient outcomes.
Previous Experience in Pharmaceutical Development
Prior to her current position, Li held several roles in pharmaceutical development. She worked at Arena Pharmaceuticals as an Associate Fellow in Formulations from 2013 to 2015. Before that, she was involved in Drug Product Development at Medicis Pharmaceutical Corporation from 2010 to 2013. Her experience includes significant contributions to formulation strategies and product development processes.
Early Career in Formulations
Li began her career in the pharmaceutical industry at Celera Genomics, where she worked as a Senior Scientist in Formulations for one year from 2003 to 2004. She also served as a Research Scientist II in Formulations at SUGEN from 2001 to 2003. These early roles provided her with foundational expertise in drug formulation and development.
Educational Background in Pharmaceutics
Chingyuan (Rebecca) Li earned her Ph.D. in Pharmaceutics from the University of Minnesota. This academic background equipped her with in-depth knowledge of drug delivery systems and formulation science, which she applies in her professional roles within the pharmaceutical industry.